PE20020267A1 - Sales estables de acido o-acetilsalicilico con aminoacidos basicos - Google Patents
Sales estables de acido o-acetilsalicilico con aminoacidos basicosInfo
- Publication number
- PE20020267A1 PE20020267A1 PE2001000717A PE2001000717A PE20020267A1 PE 20020267 A1 PE20020267 A1 PE 20020267A1 PE 2001000717 A PE2001000717 A PE 2001000717A PE 2001000717 A PE2001000717 A PE 2001000717A PE 20020267 A1 PE20020267 A1 PE 20020267A1
- Authority
- PE
- Peru
- Prior art keywords
- acid
- water
- basic amino
- refers
- amino acid
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title abstract 4
- 239000002253 acid Substances 0.000 title abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 4
- 239000002245 particle Substances 0.000 abstract 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 2
- 239000004471 Glycine Substances 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- 239000000725 suspension Substances 0.000 abstract 2
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 abstract 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 abstract 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000010899 nucleation Methods 0.000 abstract 1
- 229960003104 ornithine Drugs 0.000 abstract 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000719 purinergic P2Y receptor antagonist Substances 0.000 abstract 1
- 239000012429 reaction media Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000003856 thrombin receptor antagonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
SE REFIERE A UNA COMPOSICION QUE COMPRENDE a)UNA SAL DE ACIDO o-ACETILSALICILICO; CARACTERIZADO POR SU TAMANO DE PARTICULA SUPERIOR A 160µm Y UNA PROPORCION DE MAS DEL 60% DE LAS PARTICULAS CON UN TAMANO DE PARTICULA EN UN INTERVALO DE 100µm A 200µm; MEDIDA EN CONDICIONES STANDAR; b)UN AMINOACIDO BASICO SELECCIONADO DE LISINA, ARGININA, HISTIDINA, ORNITINA, ACIDO DIAMINOBUTIRICO, c)DE 5% A 15% DE GLICINA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION EN CONDICIONES ESTERILES QUE COMPRENDE COMBINAR RAPIDAMENTE SOLUCIONES DE ACIDO o-ACETILSALICILICO Y UN AMINOACIDO BASICO EN AGUA O EN UN DISOLVENTE MISCIBLE CON AGUA A UNA TEMPERATURA INFERIOR A 30°C A PRESION NORMAL, DE MODO QUE EL AMINOACIDO ESTE EN LIGERO EXCESO; ADICIONAR ACETONA Y DADO EL CASO CRISTALES DE SIEMBRA A UNA TEMPERATURA INFERIOR A 40°C A PRESION NORMAL; AGITAR NO MAS DE 20 HORAS CON UNA ENERGIA DE AGITACION NO SUPERIOR A 0,1W POR LITRO DE MEDIO DE REACCION, AISLAR EL SOLIDO, LAVAR CON UN DISOLVENTE ORGANICO Y SECAR A UNA TEMPERATURA INFERIOR A 50°C A PRESION INFERIOR A 50mB; ADICIONAR DE 5% A 30% EN PESO DE GLICINA COMO UNA SOLUCION EN AGUA O EN UN DISOLVENTE ORGANICO MISCIBLE CON AGUA A LA SOLUCION DE LA REACCION O COMO SUSPENSION A UNA SUSPENSION CRISTALIZADA DEL o-ACETILSALICILICO. TAMBIEN SE REFIERE A UN MEDICAMENTO QUE CONTIENE ANTAGONISTAS DE RECEPTORES DE ADP, GPIIb/IIIa, INHIBIDORES DE FOSFODIESTERASA, ANTAGONISTAS DE RECEPTOR DE TROMBINA, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10034802A DE10034802A1 (de) | 2000-07-18 | 2000-07-18 | Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020267A1 true PE20020267A1 (es) | 2002-06-08 |
Family
ID=7649258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000717A PE20020267A1 (es) | 2000-07-18 | 2001-07-17 | Sales estables de acido o-acetilsalicilico con aminoacidos basicos |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US6773724B2 (es) |
| EP (1) | EP1365737B1 (es) |
| JP (2) | JP2004507463A (es) |
| KR (1) | KR100773658B1 (es) |
| CN (1) | CN1205176C (es) |
| AR (1) | AR030305A1 (es) |
| AT (1) | ATE293589T1 (es) |
| AU (2) | AU7847101A (es) |
| BR (1) | BR0112538A (es) |
| CA (1) | CA2416288C (es) |
| CR (1) | CR6888A (es) |
| CZ (1) | CZ300337B6 (es) |
| DE (2) | DE10034802A1 (es) |
| DK (1) | DK1365737T3 (es) |
| EC (1) | ECSP034437A (es) |
| ES (1) | ES2241849T3 (es) |
| GT (1) | GT200100134A (es) |
| HR (1) | HRP20030108B1 (es) |
| HU (1) | HUP0302053A3 (es) |
| IL (2) | IL153873A0 (es) |
| MX (1) | MXPA03000510A (es) |
| MY (1) | MY134521A (es) |
| NO (1) | NO20030222D0 (es) |
| PE (1) | PE20020267A1 (es) |
| PL (1) | PL204593B1 (es) |
| PT (1) | PT1365737E (es) |
| RS (1) | RS50329B (es) |
| SK (1) | SK286162B6 (es) |
| SV (1) | SV2002000557A (es) |
| TW (1) | TWI299729B (es) |
| UY (1) | UY26841A1 (es) |
| WO (1) | WO2002005782A2 (es) |
| ZA (1) | ZA200300469B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| DE10202019A1 (de) * | 2002-01-18 | 2003-07-24 | Bayer Ag | Stabile Salze von o-Acetylsalicylsäure mit basischen Aminosäuren II |
| US8142810B2 (en) | 2002-05-30 | 2012-03-27 | The Procter & Gamble Company | Dietary method for modulating glucose metabolism and associated conditions and increasing longevity |
| ATE442352T1 (de) * | 2003-05-16 | 2009-09-15 | Cephalon France | Verfahren zur herstellung von modafinil |
| CA2576971A1 (en) * | 2004-08-20 | 2006-03-02 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| US20060166901A1 (en) * | 2005-01-03 | 2006-07-27 | Yu Ruey J | Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids |
| DE102005025283A1 (de) * | 2005-06-02 | 2006-12-07 | Bayer Healthcare Ag | Stabiler Wirkstoffkomplex von Salzen der o-Acetylsalicylsäure mit basischen Aminosäuren und Glycin |
| DE102005049293A1 (de) * | 2005-10-15 | 2007-04-26 | Bayer Healthcare Ag | Kombinationspräparate von Salzen oder o-Acetylsalicylsäure |
| US20090221703A1 (en) | 2006-07-09 | 2009-09-03 | Chongxi Yu | High penetration composition and uses thereof |
| EP2610242A1 (en) | 2006-07-09 | 2013-07-03 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of aspirin |
| US20090238763A1 (en) | 2006-07-09 | 2009-09-24 | Chongxi Yu | High penetration compositions and uses thereof |
| KR20210103586A (ko) * | 2007-06-04 | 2021-08-23 | 테크필즈 인크 | 매우 높은 피부 및 막 침투율을 가지는 비스테로이드성 소염제(ｎｓａｉａ) 약물전구체 및 이들의 새로운 의약적 용도 |
| DE102008004386A1 (de) | 2008-01-14 | 2009-07-23 | Activaero Gmbh | Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen |
| CN101314029B (zh) * | 2008-06-18 | 2010-12-08 | 四川省农业科学院实验场 | 乙酰水杨酸肽及其制备方法 |
| US20100120727A1 (en) * | 2008-11-12 | 2010-05-13 | Kyphia Pharmaceuticals, Inc. | Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof |
| CA3213470A1 (en) | 2008-12-04 | 2010-06-10 | Chongxi Yu | High penetration compositions and their applications |
| CA2766048A1 (en) * | 2009-06-25 | 2010-12-29 | Tetra, Sia | Novel acetylsalicylic acid salts |
| CN101633624B (zh) * | 2009-08-04 | 2013-05-01 | 蚌埠丰原医药科技发展有限公司 | 改进的赖氨匹林的制备方法 |
| FR2950625B1 (fr) * | 2009-09-30 | 2016-12-02 | Holis Tech | Procede de preparation d'un sel d'acide o-acetylsalicylique d'un acide amine basique et composition obtenue |
| FR2965261B1 (fr) | 2009-09-30 | 2012-10-26 | Holis Technologies | Procede de preparation d'un sel d'acide o-acetylsalicylique d'un acide amine basique et composition obtenue par ce procede |
| FR2973370B1 (fr) * | 2011-03-29 | 2013-05-03 | Holis Technologies | Procede a faible cout pour la preparation d'un acide o-acetylsalicyclique et d'un acide amine basique |
| CN102503845A (zh) * | 2011-09-28 | 2012-06-20 | 广州普星药业有限公司 | 一种dl-赖氨酸阿司匹林盐的制备方法及其应用 |
| EP4356912A3 (en) | 2012-01-18 | 2024-10-30 | Techfields Pharma Co., Ltd. | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions |
| CN102976962B (zh) * | 2012-11-20 | 2015-02-04 | 南京工业大学 | L-鸟氨酸阿司匹林复盐及其制备方法和应用 |
| FR3021654B1 (fr) * | 2014-05-28 | 2016-06-24 | Unither Pharmaceuticals | Procede de preparation d'un sel d'acide acetylsalicylique et d'un acide amine basique |
| US10882811B2 (en) * | 2016-12-23 | 2021-01-05 | Aspiair Gmbh | Synthesis of lysine acetylsalicylate glycine particles |
| JP7335232B2 (ja) * | 2017-05-30 | 2023-08-29 | ローシャン ファーマシューティカルズ，インコーポレーテッド | 安定な滅菌性且つ結晶性ｏ－アセチルサリチル酸（アスピリン）のバイアル内堆積物 |
| WO2019026992A1 (ja) * | 2017-08-03 | 2019-02-07 | 参天製薬株式会社 | クロルヘキシジンを含有する医薬組成物 |
| CN113105326A (zh) * | 2021-03-24 | 2021-07-13 | 海南卓华制药有限公司 | 赖氨匹林的制备方法及应用 |
| CN114478287A (zh) * | 2021-12-31 | 2022-05-13 | 蚌埠丰原医药科技发展有限公司 | 一种赖氨匹林晶型及制备方法和应用 |
| US20250073250A1 (en) | 2022-01-05 | 2025-03-06 | Aspiair Gmbh | Improved synthesis of lysine acetylsalicylate - Glycine particles |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2115060A1 (en) * | 1970-11-26 | 1972-07-07 | Metabio | Freeze-dried acetylsalicylates of lysine and arginine - easily prepd derivs of aspirin |
| ES388158A1 (es) * | 1971-02-11 | 1974-03-16 | Liade Sa Lab | Procedimiento de obtencion de sales solubles del acido ace-til salicilico. |
| JPS4856815A (es) * | 1971-11-13 | 1973-08-09 | ||
| JPS55127345A (en) * | 1979-03-23 | 1980-10-02 | Kyowa Hakko Kogyo Co Ltd | Preparation of acetylsalicylic acid salt |
| JPS5610110A (en) * | 1979-07-06 | 1981-02-02 | Green Cross Corp:The | Acetyl salicylate salt preparation for injection |
| JPS56113741A (en) * | 1980-02-13 | 1981-09-07 | Mitsui Toatsu Chem Inc | Preparation of crystal of acetylsalicylic acid salt |
| JPS5721345A (en) * | 1980-07-15 | 1982-02-04 | Mitsui Toatsu Chem Inc | Purification of acetylsalicylate salt |
| CS247688B1 (cs) * | 1984-12-22 | 1987-01-15 | Evzen Kasafirek | Způsob výroby soli lysinu s kyselinou acetylsalicylovou |
| JPS632929A (ja) * | 1986-06-20 | 1988-01-07 | Kao Corp | アセチルサリチル酸製剤 |
| EP0499142A3 (en) * | 1991-02-09 | 1993-05-05 | Hoechst Aktiengesellschaft | Potentiation of the antireactive-antiasthmatic effect of inhaled loop diuretics by inhaled non steroidal anti-flammatory drugs |
| DE4332093C2 (de) * | 1993-09-22 | 1995-07-13 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit dem Wirkstoff Acetylsalicylsäure und Verfahren zu seiner Herstellung |
-
2000
- 2000-07-18 DE DE10034802A patent/DE10034802A1/de not_active Withdrawn
-
2001
- 2001-07-05 SK SK67-2003A patent/SK286162B6/sk not_active IP Right Cessation
- 2001-07-05 MX MXPA03000510A patent/MXPA03000510A/es active IP Right Grant
- 2001-07-05 HU HU0302053A patent/HUP0302053A3/hu unknown
- 2001-07-05 HR HR20030108A patent/HRP20030108B1/xx not_active IP Right Cessation
- 2001-07-05 AU AU7847101A patent/AU7847101A/xx active Pending
- 2001-07-05 AU AU2001278471A patent/AU2001278471B2/en not_active Ceased
- 2001-07-05 KR KR1020037000713A patent/KR100773658B1/ko not_active Expired - Fee Related
- 2001-07-05 CA CA002416288A patent/CA2416288C/en not_active Expired - Fee Related
- 2001-07-05 PT PT01956511T patent/PT1365737E/pt unknown
- 2001-07-05 CZ CZ20030164A patent/CZ300337B6/cs not_active IP Right Cessation
- 2001-07-05 BR BR0112538-9A patent/BR0112538A/pt not_active IP Right Cessation
- 2001-07-05 IL IL15387301A patent/IL153873A0/xx unknown
- 2001-07-05 RS YUP-20/03A patent/RS50329B/sr unknown
- 2001-07-05 WO PCT/EP2001/007669 patent/WO2002005782A2/de not_active Ceased
- 2001-07-05 DE DE50105985T patent/DE50105985D1/de not_active Expired - Lifetime
- 2001-07-05 DK DK01956511T patent/DK1365737T3/da active
- 2001-07-05 CN CNB018158811A patent/CN1205176C/zh not_active Expired - Fee Related
- 2001-07-05 JP JP2002511715A patent/JP2004507463A/ja active Pending
- 2001-07-05 AT AT01956511T patent/ATE293589T1/de not_active IP Right Cessation
- 2001-07-05 PL PL365648A patent/PL204593B1/pl not_active IP Right Cessation
- 2001-07-05 ES ES01956511T patent/ES2241849T3/es not_active Expired - Lifetime
- 2001-07-05 EP EP01956511A patent/EP1365737B1/de not_active Expired - Lifetime
- 2001-07-11 GT GT200100134A patent/GT200100134A/es unknown
- 2001-07-16 US US09/906,497 patent/US6773724B2/en not_active Expired - Lifetime
- 2001-07-16 UY UY26841A patent/UY26841A1/es not_active Application Discontinuation
- 2001-07-16 TW TW090117276A patent/TWI299729B/zh active
- 2001-07-16 MY MYPI20013365A patent/MY134521A/en unknown
- 2001-07-16 AR ARP010103378A patent/AR030305A1/es unknown
- 2001-07-17 PE PE2001000717A patent/PE20020267A1/es not_active Application Discontinuation
- 2001-07-17 SV SV2001000557A patent/SV2002000557A/es unknown
-
2003
- 2003-01-09 IL IL153873A patent/IL153873A/en not_active IP Right Cessation
- 2003-01-16 NO NO20030222A patent/NO20030222D0/no not_active Application Discontinuation
- 2003-01-17 CR CR6888A patent/CR6888A/es unknown
- 2003-01-17 ZA ZA200300469A patent/ZA200300469B/en unknown
- 2003-01-17 EC EC2003004437A patent/ECSP034437A/es unknown
-
2004
- 2004-08-09 US US10/915,652 patent/US7449198B2/en not_active Expired - Fee Related
-
2012
- 2012-03-28 JP JP2012072662A patent/JP2012131824A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020267A1 (es) | Sales estables de acido o-acetilsalicilico con aminoacidos basicos | |
| Beckerle et al. | Inhibitors of dynein activity block intracellular transport in erythrophores | |
| JP2012501681A5 (es) | ||
| AR026223A1 (es) | Concentrados de suspenciones, no acuosos o pobres en agua, de mezclas de sustancias activas para la proteccion de plantas. | |
| RU2012131297A (ru) | Водная антиперспирантная/дезодорантная композиция | |
| CL2012001538A1 (es) | Método para reducir el estrés de plantas por temperatura que comprende aplicar 50-200 g de ácido 4-oxo-4-(2-feniletil) aminobutírico, 4-oxo-4-(2-feniletil) aminobutirato de metilo o ácido 4-oxo-4-(4-feniletil) aminobutírico /100 kg de semilla. | |
| ES2621257T3 (es) | Ésteres de ciclopropanocarboxilato de análogos de purinas | |
| AR088460A1 (es) | Formulaciones de etanercept estabilizadas con aminoacidos | |
| UA115043C2 (uk) | Амідні похідні n-карбамідзаміщених амінокислот як модулятори формілпептидного рецептора 1 (fprl-1) | |
| CL2013002243A1 (es) | Granulado que comprende un nucleo solido en el cual estan dispuestos acido gamma-hidroxibutirico o una sal del mismo, compuestos que pueden generar evolucion de gas, diluyentes, un aglutinante y una membrana de recubrimiento; composicion farmaceutica; y uso para tratar la narcolepsia y abstinencia alcoholica. | |
| AR062224A1 (es) | Tetrazolilos macrociclicos como inhibidores de serina proteasa ns3 del virus de hepatitis c y composiciones farmaceuticas que los comprenden. | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR048966A1 (es) | Limpiadores liquidos personales que comprenden un sistema estructurante combinado de acido graso y almidon expansible o soluble en agua | |
| NI200800227A (es) | Acidos 1,3-dioxano carboxilicos | |
| AR057034A1 (es) | Metodos para purificar tigeciclina | |
| AR017066A1 (es) | Cristales de glicoproteina, de enlazamiento cruzado con carbohidrato | |
| PE26898A1 (es) | Sales edulcorantes | |
| AR113853A1 (es) | Pirazolopirimidinas que tienen actividad contra el vsr | |
| PE20061014A1 (es) | Clorhidrato de lercanidipina amorfo | |
| PE20060025A1 (es) | Formulaciones liquidas administrables por via dermica para combatir artropodos parasitos en animales | |
| PE20131327A1 (es) | Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparacion, y las composiciones farmaceuticas que la contienen | |
| AR071066A1 (es) | Derivados de (hetero) aril-ciclohexano | |
| Liang et al. | SPRC protects hypoxia and re-oxygenation injury by improving rat cardiac contractile function and intracellular calcium handling | |
| EA200800752A1 (ru) | Стабильные при хранении препараты сульфонамидов | |
| PE20030731A1 (es) | Sales estables del acido o-acetilsalicilico con aminoacidos basicos ii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |